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Purpose of the study
There is an ongoing debate about when to use efavirenz
(EFV) or nevirapine (NVP) for first line antiretroviral
treatment (ART) in developing countries, fuelled by
EFV’s link with teratogenicity in rats and NVP’s risk of
hepatotoxicity with increasing CD4 levels and it’s inter-
actions with Rifampicin. This paper compares the effec-
tiveness of these two drugs in a multicentre adult
cohort of ART patients attending public health facilities
in South Africa.
Methods
A retrospective cohort analysis of routine data on 27350
ART naïve adults initiated between March 2004 and
March 2007 at 56 public health sites across 4 provinces
was completed. Stata 9 was used to conduct analyses
which included Kaplan Meir survival analysis, logistic
regression, generalised estimating equations and Cox
proportional hazard models.
Summary of results
Median follow up time was 9.3 months and median
baseline CD4 count 113 cells/mL (IQR= 57-165). Multi-
variate analyses showed patients receiving first line regi-
mens containing EFV to have been more likely to
suppress virologically both at 6 months (OR=1.30; 95%
CI:1.11-1.54) and at any time between 6 and 36 months
(OR= 1.28; 95%CI:1.16-1.41), less likely to change regi-
men (OR=0.53; 95%CI:0.48-0.59) and more likely to die
(AHR= 1.24; 95%CI:1.07-1.45). A subset analysis of
18527 patients with pregnancy and tuberculosis status
reported showed no difference in hazard rates for death
between the two groups (AHR=1.17; 95%CI:0.99-1.37).
Conclusions
This data shows superior results for patients on EFV
with respect to all outcomes except death. Retrieval of
missing data about pregnancy and tuberculosis status
may push this last association toward the null. Protease
inhibitors are an alternative to non-nucleoside reverse
transcriptase inhibitors (NNRTIs) for first line use; but
are currently too costly. There is an urgent need for
further research into currently available NNRTIs; as well
as the development of new antiretrovirals for resource
depleted settings. In the interim the developing world
needs to increase access and bring down the cost of
existing drugs and implement more efficient treatment
strategies.
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